Crossmark

The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration’s Adverse Event Reporting System

Crossref DOI link: https://doi.org/10.1016/j.jsps.2023.05.023

Published Print: 2023-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Alsuhaibani, Deemah S.

Edrees, Heba H.

Alshammari, Thamir M
License Information

Text and Data Mining valid from 2023-07-01

Version of Record valid from 2023-05-25
More Information

This article is maintained by: Elsevier

Article Title: The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration’s Adverse Event Reporting System

Journal Title: Saudi Pharmaceutical Journal

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.jsps.2023.05.023

Content Type: article

Copyright: © 2023 The Authors. Published by Elsevier B.V. on behalf of King Saud University.

Document is current

Any future updates will be listed below